Keros Therapeutics Files 8-K: Other Events

TL;DR

Keros Therapeutics dropped an 8-K for 'Other Events' on Sept 30. What's the news?

AI Summary

Keros Therapeutics, Inc. filed an 8-K on September 30, 2024, reporting an event that occurred on the same date. The filing is under the 'Other Events' category, indicating a significant development not covered by other standard 8-K items. Specific details of the event are not provided in the excerpt, but the filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing signals a material event has occurred for Keros Therapeutics, requiring public disclosure. Investors should look for subsequent filings or press releases to understand the nature and impact of this event.

Risk Assessment

Risk Level: medium — The filing of an 8-K under 'Other Events' suggests a potentially significant, but currently undisclosed, event that could impact the company's stock.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — Registrant
• 0001664710-24-000078 (filing_id) — Accession Number
• September 30, 2024 (date) — Date of Report
• 1050 Waltham Street, Suite 302 (address) — Principal Executive Offices
• Lexington, Massachusetts (location) — Principal Executive Offices
• 02421 (zip_code) — Principal Executive Offices
• 617-314-6297 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

• kros-20240930.htm (8-K) — 33KB
• 0001664710-24-000078.txt ( ) — 156KB
• kros-20240930.xsd (EX-101.SCH) — 2KB
• kros-20240930_lab.xml (EX-101.LAB) — 22KB
• kros-20240930_pre.xml (EX-101.PRE) — 13KB
• kros-20240930_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 30, 2024, Keros Therapeutics, Inc. (the "Company") announced that it completed enrollment of the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension. A total of 113 patients were enrolled, exceeding the initial target enrollment of 90 patients for the trial. The Company expects to present topline data in the second quarter of 2025. This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expected timing for data readout for the TROPOS trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize, including those risk factors discussed or referred to in the Company's filings with the SEC, including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: September 30, 2024

View Full Filing

View this 8-K filing on SEC EDGAR